EGFR and cancer: Aberrantly expressed EGFr, inappropriate activation of intracellular signaling mediated by mutated EGFr, or both can induce cancer initiation and progression, and EGFr TKIs are current first‐line therapies for various cancers linked to EGFr signaling (Loriot et al., 2008).